Evidence map›Paper›PMID 31827319›Full record

ArticleDrug design, development and therapy2019

Radioprotective Potential of Sulindac Sulfide to Prevent DNA Damage Due to Ionizing Radiation.

Seyedeh Atekeh Torabizadeh, Mehdi Rezaeifar, Ali Jomehzadeh, Farzaneh Nabizadeh Haghighi, Mehdi Ansari

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Seyedeh Atekeh TorabizadehPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0003-1245-984X
Mehdi RezaeifarPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0002-1065-3035
Ali JomehzadehDepartment of Medical Physics, Faculty of Medicine, Medical Physics Department, Radiotherapy & Oncology Unit, Shafa Kerman Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Farzaneh Nabizadeh HaghighiPharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Mehdi AnsariDrug and Food Control Department, Kerman University of Medical Sciences, Kerman, Iran.ORCID 0000-0003-4637-553X
Kerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PURPOSE: In this research, the radioprotective effect of SS was investigated against genotoxicity and lipid peroxidation induced by ionizing radiation in the human blood lymphocytes.

methodsIn this study, the human blood samples were pretreated with SS at different concentrations (10, 25, 50, 100 and 250 μM) and then were exposed to IR at a dose of 1.5 Gy. The micronucleus (MN) assay was used to indicate the radioprotective effects of SS on exposed cells. Total antioxidant activity of the SS was measured by using FRAP and DPPH assay. Also, the malondialdehyde (MDA) levels and the activity of superoxide dismutase (SOD) on the exposed cells were evaluated.

resultsIt was found that SS decreased the percentage of MN induced by IR in exposed cells. Maximum reduction in the frequency of MN was observed at 250 μM of SS (87%) that provides the highest degree of protection against IR. On the other hand, pretreatment at 250 μM of SS inhibited IR-induced oxidative stress, which led to a decrease in the MN frequencies and MDA levels, while SOD activity showed an increase in the exposed cells.

conclusionIt could be concluded that SS as a good radioprotective agent protects the human normal cells against the oxidative stress and genetic damage induced by IR.

Indexed as

DNA DamageAntioxidantsDose-Response Relationship, DrugHumansLipid PeroxidationLymphocytesMalondialdehydeMolecular StructureRadiation ProtectionStructure-Activity RelationshipSulindacSuperoxide DismutaseAntioxidantsMalondialdehydeSulindacsulindac sulfideSuperoxide DismutaseDNA damagegenotoxicitylipid peroxidationMNradioprotectivesulindac sulfide

Identifiers

PMID31827319
PMCPMC6902880
OpenAlexW2992960195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.